NimbleGen, Prepping for IPO, Says Revenues Grew 200 Percent Since 2004 | GenomeWeb
NEW YORK (GenomeWeb News) – NimbleGen, which late last week said it has filed for an initial public offering with the Securities and Exchange Commission, said revenues increased 200 percent and that it has accumulated $20 million in net losses over the past three years.
 
In the SEC document, the company said revenues increased from $4.5 million in 2004 to $13.5 million in 2006 on increasing sales. The firm also said grant revenue declined during that period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.